Skip to main content
SpringerLink
Log in

Breast-Cancer Prevention with Antiestrogens

  • Chapter
Hormone Therapy in Breast and Prostate Cancer

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 338 Accesses

Abstract

In 1936 Lacassagne suggested that if breast cancer was caused by a special genetic susceptibility of the breast to estrogen, then perhaps a therapeutic antagonist could be found to prevent the disease (1).It is now 40 years since the first description of the target, the estrogen receptor (ER), by Elwood Jensen (2)and the report of the first nonsteroidal antiestrogen MER25 by Leonard Lerner (3).Regrettably, MER25 was not useful clinically, but a related compound, tamoxifen, first reported by Harper and Walpole as an antifertility agent in animals (4,5),subsequently has become the endocrine therapy of choice for all stages of breast cancer (6,7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 1936; 243:217–225.

    Google Scholar 

  2. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962; 18:387–414.

    CAS  Google Scholar 

  3. Lerner LJ, Holthaus JF, Thompson CR. A nonsteroidal estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)- 1-phenyl-2-p-methoxyphenylethanol. Endocrinology 1958; 63:295–318.

    Article  PubMed  CAS  Google Scholar 

  4. Harper MJK, Walpole AL. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reprod Fertil 1967; 13:101–119.

    PubMed  CAS  Google Scholar 

  5. Harper MJK, Walpole AL. Mode of action of I.C.I. 46,474 in preventing implantation in rats. J Endocrinol 1967; 37:83–92.

    Article  PubMed  CAS  Google Scholar 

  6. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. Eighth Cain Memorial Award Lecture. Cancer Res 1990; 50:4177–4189.

    PubMed  CAS  Google Scholar 

  7. Jordan VC. Current view of the use of tamoxifen for the treatment and prevention of breast cancer. Gaddum Memorial Lecture. Br J Pharmacol 1993; 110:507–517.

    PubMed  CAS  Google Scholar 

  8. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451–1467.

    Google Scholar 

  9. Madigan MP, Ziegler RG, Benichou J, Byrne C, and Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995; 87:1681–1685.

    Article  PubMed  CAS  Google Scholar 

  10. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641–1647.

    Article  PubMed  CAS  Google Scholar 

  11. Jordan VC, MacGregor JI, Tonetti DA. Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Osteoporos Int 1997; 7:S52–57.

    Article  PubMed  Google Scholar 

  12. Jordan VC. Tamoxifen: the herald of a new era of preventive therapeutics. J Natl Cancer Inst 1997; 89:747–749.

    Article  PubMed  CAS  Google Scholar 

  13. Jordan VC. Effect of tamoxifen (I.C.I. 46,474) on initiation of growth of DMBA-induced rat mammary carcinoma. Eur J Cancer 1976; 12:419–424.

    PubMed  CAS  Google Scholar 

  14. Jordan VC, Allen KE. Evaluation of the antitumor activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 1980; 16:231–251.

    Google Scholar 

  15. Gottardis MM, Jordan VC. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea- induced rat mammary carcinoma model. Cancer Res 1987; 47:4020–4024.

    PubMed  CAS  Google Scholar 

  16. Jordan VC, Lababidi MK, Mirecki DM. The anti-estrogenic and anti-tumor properties of prolonged tamoxifen therapy in C3H/OUJ mice. Eur J Cancer 1990; 26:718–721.

    Article  PubMed  CAS  Google Scholar 

  17. Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 1991; 83:492–496.

    Article  PubMed  CAS  Google Scholar 

  18. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; 2:282.

    Article  PubMed  CAS  Google Scholar 

  19. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989; 60:126–131.

    PubMed  CAS  Google Scholar 

  20. Powles TJ, Tillyer CR, Jones AL, Ashley SE, Treleaven J, Davey JB, McKinna JA. Prevention of breast cancer with tamoxifen; an update of the Royal Marsden Pilot Program. Eur J Cancer 1990; 26:680–648.

    Article  PubMed  CAS  Google Scholar 

  21. Jordan VC, Robinson SP. Species specific pharmacology of antiestrogens: role of metabolism. Fed Proc 1987; 46:1870–1874.

    PubMed  CAS  Google Scholar 

  22. Jordan VC, Phelps E, Lindgren JU. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10:31–35.

    Article  PubMed  CAS  Google Scholar 

  23. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48:812–815.

    PubMed  CAS  Google Scholar 

  24. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852–6.

    PubMed  CAS  Google Scholar 

  25. Ward RL, Morgan G, Dalley D, Kelly PJ. Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner 1993; 22:87–94.

    Article  PubMed  CAS  Google Scholar 

  26. Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I, Mouridsen HT. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994; 12:992–997.

    PubMed  CAS  Google Scholar 

  27. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115:860–864.

    PubMed  CAS  Google Scholar 

  28. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish tamoxifen trial. Br Med J 1991; 303:435–437.

    Article  CAS  Google Scholar 

  29. Rutqvist LE, Matteson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993; 85:1398–1406.

    Article  PubMed  CAS  Google Scholar 

  30. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997; 89:776–782.

    Article  PubMed  CAS  Google Scholar 

  31. Williams GM, latropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 1993; 14:315–317.

    Article  PubMed  CAS  Google Scholar 

  32. Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996; 32A;1464–1476.

    Article  PubMed  Google Scholar 

  33. Jordan VC. Tamoxifen and tumorigenicity: a predictable concern. J Natl Cancer Inst 1995; 87:623–626.

    Article  PubMed  CAS  Google Scholar 

  34. Martin EA, Rich KJ, White IN, Woods KL, Powles TJ, Smith LL. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995; 16:1651–1654.

    Article  PubMed  CAS  Google Scholar 

  35. Phillips DH, Carmichael PL, Hewer A, Cole KJ, Hardcastle IR, Poon GK, et al. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 1996; 17:89–94.

    Article  PubMed  CAS  Google Scholar 

  36. Dal Cin P, Timmerman D, Van den Berghe I, Wanschura S, Kazmierczak B, Vergote I, et al. Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen. Cancer Res 1998; 58:2278–2281.

    Google Scholar 

  37. Seidman H, Mushinski MH, Gelb SK, Silverberg E. Probabilities of eventually developing or dying of cancer: United States, 1985. CA Cancer J Clin 1985; 35:36–41.

    Article  PubMed  CAS  Google Scholar 

  38. Newman B, Austin MA, Lee M, King, MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high risk families. Proc Natl Acad Sci USA 1988; 85:3044–3048.

    Article  PubMed  CAS  Google Scholar 

  39. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991; 48:232–242.

    PubMed  CAS  Google Scholar 

  40. Easton DF, Bishop DT, Ford D, Crockford GP, and the Breast Cancer Linkage Consortium. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993; 52:678–701.

    Google Scholar 

  41. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:1401–1408.

    Article  PubMed  CAS  Google Scholar 

  42. Miki Y, Swenson J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene, BRCA 1. Science 1994; 266:66–71.

    Article  PubMed  CAS  Google Scholar 

  43. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA 2, to chromosome 13q12–13. Science 1994; 265:2088–2090.

    Article  PubMed  CAS  Google Scholar 

  44. King MC, Rowell S, Love SM. Inherited breast and ovarian cancer. What are the risks? What are the choices? JAMA 1993; 269:1975–1980.

    Article  PubMed  CAS  Google Scholar 

  45. Malkin D, Li, FP, Strong LC, Fraumeni JF Jr., Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233–1238.

    Article  PubMed  CAS  Google Scholar 

  46. Sidransky D, Tokino T, Helzlsouer K, Zehnbauer B, Rausch G, Shelton B, et al. Inherited p53 gene mutations in breast cancer. Cancer Res 1992; 52:2984–2986.

    PubMed  CAS  Google Scholar 

  47. Ottman R, Pike MC, King MC, Henderson BE. Practical guide for estimating risk for familial breast cancer. Lancet 1983; 3:556–558.

    Article  Google Scholar 

  48. Anderson DE, Badzioch MD. Risk of familial breast cancer. Cancer 1985; 56:383–387.

    Article  PubMed  CAS  Google Scholar 

  49. Ries LAG, Miller BA, Hankey BF, et al. (eds.) SEER Cancer Statistics Review, 1973–1991. NIH Pub. 94-2789. USDHHS National Cancer Institute, Bethesda, MD, 1994.

    Google Scholar 

  50. MacMahon B, Trichopoulos D, Brown J, Andersen AP, Aoki K, Cole P, et al. Age at menarche, probability of ovulation and breast cancer risk. Intl J Cancer 1982; 29:13–16.

    Article  CAS  Google Scholar 

  51. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972; 48:605–613.

    PubMed  CAS  Google Scholar 

  52. MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, et al. Age at first birth and breast cancer risk. Bull WHO 1970; 43:209–221.

    PubMed  CAS  Google Scholar 

  53. Daling JR, Malone KE, Voight LF, White E, Weiss, NS. Risk of breast cancer among young women: relationship to induced abortion. J Natl Cancer Inst 1994; 86:1584–1592.

    Article  PubMed  CAS  Google Scholar 

  54. Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Willett WC. Pregnancy termination in relation to risk of breast cancer. JAMA 1996; 275:283–287.

    Article  PubMed  CAS  Google Scholar 

  55. Harris BM, Eklund G, Meirik O, Rutqvist LE, Wiklund K. Risk of cancer of the breast after legal abortion during the first trimester: a Swedish register study. BMJ 1989; 299:1430–1432.

    Article  PubMed  CAS  Google Scholar 

  56. Melbye M, Wohlfahrt J, Olsen JH, Frisch M, Westergaard T, Helweg-Larsen K, Andersen PK. Induced abortion and the risk of breast cancer. N Engl J Med 1997; 336:81–85.

    Article  PubMed  CAS  Google Scholar 

  57. Layde PM, Webster LA, Baughman AL, Wingo PA, Rubin GL, Ory HW. The independent associations of parity, age at first full-term pregnancy, and duration of breastfeeding with the risk of breast cancer. J Clin Epidemiol 1989; 42:963–973.

    Article  PubMed  CAS  Google Scholar 

  58. Kvale G, Heuch I. Lactation and cancer risk: is there a relation specific to breast cancer? J Epidemiol Community Health 1988; 42:30–37.

    Article  PubMed  CAS  Google Scholar 

  59. Newcomb PA, Storer BE, Longnecker MP, Mittendorf R, Greenberg ER, Clapp RW, et al. Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med 1994; 330:81–87.

    Article  PubMed  CAS  Google Scholar 

  60. Frisch RE, Gotz-Welbergen AV, McArthur JW, Albright T, Witschi J, Bullen B, et al. Delayed menarche and amenorrhea of college athletes in relation to age of onset of training. JAMA 1981; 246:1559–1563.

    Article  PubMed  CAS  Google Scholar 

  61. Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86:1403–1408.

    Article  PubMed  CAS  Google Scholar 

  62. Dorgan JF, Brown C, Barrett M, Splansky GL, Kreger BE, D’Agostino RB, et al. Physical activity and risk of breast cancer in the Framingham heart study. Am J Epidemiol 1994; 139:662–669.

    PubMed  CAS  Google Scholar 

  63. de Waard F, Baanders-van Halewijn E. A prospective study in general practice on breast cancer risk in postmenopausal women. Intl J Cancer 1974; 14:153–160.

    Article  Google Scholar 

  64. London SJ, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE. Prospective study of relative weight, height, and risk of breast cancer. JAMA 1989; 262:2853–2858.

    Article  PubMed  CAS  Google Scholar 

  65. Malone KE, Daling JR, Weiss NS. Oral contraceptives in relation to breast cancer. Epidemiol Rev 1993; 15:80–97.

    PubMed  CAS  Google Scholar 

  66. Meirik O, Lund E, Adami HO, Bergstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use and breast cancer in younger women. A joint national case control study in Sweden and Norway. Lancet 1986; 2:650–654.

    Article  PubMed  CAS  Google Scholar 

  67. UK National Case-Control Study Group. Oral contraceptive use and breast cancer risk in young women. Lancet 1989; 1:976–982.

    Google Scholar 

  68. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265:1985–1990.

    Article  PubMed  CAS  Google Scholar 

  69. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a metaanalysis. Obstet Gynecol 1992; 79:286–294.

    PubMed  CAS  Google Scholar 

  70. Dupont WD, Page D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312:146–151.

    Article  PubMed  CAS  Google Scholar 

  71. Morrow M. Management of nonpalpable breast masses. PPO Updates 1990; 4:1–11.

    Google Scholar 

  72. Rubin E, Visscher DW, Alexander RW, Urist MM, Maddox WA. Proliferative disease and atypia in biopsies performed for nonpalpable lesions detected mammographically. Cancer 1988; 61:2077–2082.

    Article  PubMed  CAS  Google Scholar 

  73. Skolnick MH, Cannon-Albright LA, Goldgar DE, Ward JH, Marshall CJ, Schumann GB, et al. Inheritance of proliferative breast disease in breast cancer kindreds. Science 1990; 250:1715–1720.

    Article  PubMed  CAS  Google Scholar 

  74. Morrow M, Schnitt SJ. Lobular carcinoma in situ, in Diseases of the Breast(Harris JR, Lippman ME, Morrow M, Hellman S, eds). Lippincott-Raven, Philadelphia, PA, 1996; pp 369–374.

    Google Scholar 

  75. Land CE, McGregor DH. Breast cancer incidence among atomic bomb survivors: implications for radiobiologic risk at low doses. J Natl Cancer Inst 1979; 62:17–21.

    PubMed  CAS  Google Scholar 

  76. Hildreth NG, Shore RE, Dvoretsky PM. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989; 321:1281–1284.

    Article  PubMed  CAS  Google Scholar 

  77. Miller AB, Howe GR, Sherman GJ, Lindsay JP, Yaffe MJ, Dinner PJ, et al. Mortality from breast cancer after irradiation during fluoroscopic examinations in patients being treated for tuberculosis. N Engl J Med 1989; 321:1285–1289.

    Article  PubMed  CAS  Google Scholar 

  78. Hunter DJ, Willett WC. Dietary factors, in Diseases of the Breast(Harris JR, Lippman ME, Morrow M, Hellman S, eds). Lippincott-Raven, Philadelphia, PA, 1996; pp 201–212.

    Google Scholar 

  79. Hunter DJ, Spiegelman D, Adami HO, Beeson L, van den Brandt PA, Folsom AR, et al. Cohort studies of fat intake and the risk of breast cancer: a pooled analysis. N Engl J Med 1996; 334:356–361.

    Article  PubMed  CAS  Google Scholar 

  80. Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. A meta-analysis of alcohol consumption in relation to breast cancer risk. JAMA 1988; 260:652–656.

    Article  PubMed  CAS  Google Scholar 

  81. Young TB. A case-control study of breast cancer and alcohol consumption habits. Cancer 1989; 64:552–558.

    Article  PubMed  CAS  Google Scholar 

  82. Gapstur SM, Potter JD, Sellers TA, Folsom AR. Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol 1992; 136:1221–1231.

    PubMed  CAS  Google Scholar 

  83. Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW Jr. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average followup of 24 years. Am J Surg Pathol 1978; 2:225–251.

    Article  PubMed  CAS  Google Scholar 

  84. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, Rosner BA. Family history, age, and risk of breast cancer. Prospective data from the Nurses’ Health Study. JAMA 1993; 270:338–343.

    Article  PubMed  CAS  Google Scholar 

  85. Anderson DE, Badzioch MD. Combined effect of family history and reproductive factors on breast cancer risk. Cancer 1989; 63:349–353.

    Article  PubMed  CAS  Google Scholar 

  86. Brinton LA, William RR, Hoover RN, Stegens NL, Feinleib M, Fraumeni JF Jr. Breast cancer risk factors among screening program participants. J Natl Cancer Inst 1979; 62:37–44.

    PubMed  CAS  Google Scholar 

  87. Gail MH, Brinton LA, Byar DP, Coric DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879–1886.

    Article  PubMed  CAS  Google Scholar 

  88. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994; 86:620–625.

    Article  PubMed  CAS  Google Scholar 

  89. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al model for predicting individual breast cancer risk. J Natl Cancer Inst 1994; 86:600–607.

    Article  PubMed  CAS  Google Scholar 

  90. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995; 87:1681–1685.

    Article  PubMed  CAS  Google Scholar 

  91. Seidman H, Stellman SD, Mushinski MH. A different perspective on breast cancer risk factors: some implications of the nonattributable risk. CA Cancer J Clin 1982; 32:301–312.

    Article  PubMed  CAS  Google Scholar 

  92. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  93. Powles TJ, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352:98–101.

    PubMed  CAS  Google Scholar 

  94. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352:93–97.

    PubMed  CAS  Google Scholar 

  95. Jordan VC, Glusman JE, Eckert S, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multicenter double blind, randomized trials in 12,000 postmenopausal women. Proc Am Soc Clin Oncol 1998; 17:122a.

    Google Scholar 

  96. Black LJ, Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983; 32:1031–1036.

    Article  PubMed  CAS  Google Scholar 

  97. Black LJ, Goode RL. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci 1980; 26:1453–1458.

    Article  PubMed  CAS  Google Scholar 

  98. Jordan VC, Gosden B. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 1983; 113:463–468.

    Article  PubMed  CAS  Google Scholar 

  99. Powles TJ, Hickish T, Kanis JA, Tidy VA, Ashley S. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78–84.

    PubMed  CAS  Google Scholar 

  100. Baker VL, Draper M, Paul S, Allerheiligen S, Glant M, Shifren J, Jaffe RB. Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. J Clin Endocrinol Metab 1998; 83:6–13.

    Article  PubMed  CAS  Google Scholar 

  101. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1991; 83:1488–1491.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chief of Breast Surgery at Memorial Sloan-Kettering Cancer Center, Manhattan, NY

    Monica Morrow

  2. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

    V. Craig Jordan

Authors
  1. Monica Morrow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Craig Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Rd. NW Research Bldg. E501, Washington, DC, 20057, USA

    V. Craig Jordan

  2. AstraZeneca Pharmaceuticals Zeneca Pharmaceutical, Alderly Park, Alderly House, Macclesfield, SK 10 4TF, UK

    Barrington J.A. Furr

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Morrow, M., Jordan, V.C. (2009). Breast-Cancer Prevention with Antiestrogens. In: Jordan, V.C., Furr, B.J. (eds) Hormone Therapy in Breast and Prostate Cancer. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59259-152-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-152-7_10

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-471-5

  • Online ISBN: 978-1-59259-152-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation